Pharma's Market
SPECIAL REPORT
- How Stock Investors Can Play Holiday Travel
- Time Lapse World Series Is A Great Play
- Hirschhorn: Greed...or Fear
- My Top 10 Tech Toys for the Holidays
- iPhone a Better Gaming Platform Than Android?
- May Day For Dendreon
- 100% Mortgage Financing From USDA
- Holiday Tipping: Who And How Much
- Deep Discounts Should Make It a Very Tech-y Holiday
- The Richest Members of the US Congress
- New Consensus Sees Stimulus Package as Worthy Step
- Wall Street Jobs Slow to Return Despite Record Profits
- Thanksgiving Week Stuffed With Economic News
- Black Friday Deals May Not Signal Retail Comeback
- Investors to Goldman: Be Less Greedy
- UPS Sets New Rates For 2010
- Victoria's Secret Hopes to Rekindle Desire for Lingerie
- 'New Moon' Takes Record $72.7M Box Office Bite
PHARMA'S MARKET VIDEO

Cholesterol Drug Battle: Niaspan vs. Zetia
16 Nov 2009
Cardiologist Grades Cholesterol Drug Study
16 Nov 2009
Merck's Cholesterol Drugs Under Pressure
16 Nov 2009
Cholesterol Drug Battle: Merck vs. Abbott Labs
16 Nov 2009
Cholesterol Drug Battle
16 Nov 2009
Novo Nordisk CEO on Diabetes Epidemic
13 Nov 2009
RSS FEED
Reporter
6, 11, 16, 18, 31, 33, 45...hike! It may read like a quarterback's snap countdown, but those are actually the numbers of the strains of the sexually transmitted human papillomavirus (HPV) covered by the two vaccines made by GlaxoSmithKline and Merck.
But GSK is still trying to score with the shots.
![]() |
A "Lancet" editorial also points out that real progress against HPV and cervical cancer, which are a very big problem in the developing world, won't be made until guys get vaccinated. Males carry and transmit the virus. Merck is waiting for an FDA decision on whether it can sell Gardasil to guys.
Perhaps reflecting concerns about the size and growth of the market for HPV shots and GSK's late entry, investors are not enthusiastic about the prestigious publication of the company's robust new test results. As I write this, GSK shares are the biggest percentage loser in big pharma.
Time to call an audible.
Questions? Comments? and follow me on Twitter at mhuckman










